Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:Potassium 2,6-dihydroxytriazinecarboxylate
go back to main search page
Accession:CHEBI:80230 term browser browse the term
Definition:An organic molecular entity that has formula C4H2KN3O4.
Synonyms:related_synonym: Formula=C4H2KN3O4;   InChI=1S/C4H3N3O4.K/c8-2(9)1-5-3(10)7-4(11)6-1;/h(H,8,9)(H2,5,6,7,10,11);/q;+1/p-1;   InChIKey=IAPCTXZQXAVYNG-UHFFFAOYSA-M;   Oteracil potassium;   Potassium oxonate;   SMILES=[K+].[O-]C(=O)c1nc(=O)[nH]c(=O)[nH]1
 alt_id: MESH:C489337
 xref: CAS:2207-75-2;   KEGG:C15997
 xref_mesh: MESH:C489337


show annotations for term's descendants           Sort by:
Potassium 2,6-dihydroxytriazinecarboxylate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions
increases expression		 ISO
EXP		 4-hydroxystilbene inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]; Allopurinol inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]; mulberroside A inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]; polydatin inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]; Probenecid inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]; pterostilbene inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]; resveratrol inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein]
[potassium oxonate co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein; eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein]		 CTD PMID:22865646 PMID:38052408 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP
ISO		 [Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; [potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL1B protein; Allopurinol inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL1B protein]; eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL1B protein]; potassium oxonate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]
[Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]		 CTD PMID:20868668 PMID:33749747 PMID:38052408 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP		 [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 mRNA]
[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL6 protein; Allopurinol inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL6 protein]; eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL6 protein]		 CTD PMID:33749747 PMID:38052408 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Mpo myeloperoxidase multiple interactions EXP [potassium oxonate co-treated with Inosine Monophosphate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; potassium oxonate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] CTD PMID:20868668 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NOS2 mRNA] CTD PMID:33749747 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of RELA protein] CTD PMID:33749747 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 decreases expression
multiple interactions		 ISO potassium oxonate results in decreased expression of SLC22A1 mRNA; potassium oxonate results in decreased expression of SLC22A1 protein
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; mulberroside A inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]; resveratrol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein]		 CTD PMID:21909718 PMID:22865646 PMID:22967667 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc22a12 solute carrier family 22 member 12 multiple interactions
increases expression		 ISO 4-hydroxystilbene inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; Allopurinol inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; mulberroside A inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; Probenecid inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; pterostilbene inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]; Quercetin inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein]
potassium oxonate results in increased expression of SLC22A12 mRNA; potassium oxonate results in increased expression of SLC22A12 protein		 CTD PMID:21909718 PMID:22865646 PMID:22967667 NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 decreases expression
multiple interactions		 ISO potassium oxonate results in decreased expression of SLC22A2 mRNA; potassium oxonate results in decreased expression of SLC22A2 protein
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 protein]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 protein]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 protein]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 protein]		 CTD PMID:21909718 PMID:22865646 PMID:22967667 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Slc22a4 solute carrier family 22 member 4 decreases expression
multiple interactions		 ISO potassium oxonate results in decreased expression of SLC22A4 mRNA; potassium oxonate results in decreased expression of SLC22A4 protein
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]; mulberroside A inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]; polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein]		 CTD PMID:21909718 PMID:22865646 PMID:22967667 NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720 		JBrowse link
G Slc22a5 solute carrier family 22 member 5 decreases expression
multiple interactions		 ISO potassium oxonate results in decreased expression of SLC22A5 mRNA; potassium oxonate results in decreased expression of SLC22A5 protein
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]; mulberroside A inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]; polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein]		 CTD PMID:21909718 PMID:22865646 PMID:22967667 NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309 		JBrowse link
G Slc22a6 solute carrier family 22 member 6 decreases expression
multiple interactions		 ISO potassium oxonate results in decreased expression of SLC22A6 mRNA; potassium oxonate results in decreased expression of SLC22A6 protein
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; mulberroside A inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]; resveratrol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein]		 CTD PMID:21909718 PMID:22865646 PMID:22967667 NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173 		JBrowse link
G Slc2a12 solute carrier family 2 member 12 multiple interactions EXP [potassium oxonate co-treated with Hypoxanthine] results in increased expression of SLC2A12 protein; eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased expression of SLC2A12 protein] CTD PMID:38052408 NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:22,804,418...22,860,971 		JBrowse link
G Slc2a9 solute carrier family 2 member 9 multiple interactions
increases expression		 ISO
EXP		 Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 mRNA]; Drugs, Chinese Herbal inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]; mulberroside A inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]; Plant Extracts inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 mRNA]; Plant Extracts inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]; polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]; Probenecid inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 mRNA]; Probenecid inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]; Quercetin inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 mRNA]; Quercetin inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]; resveratrol inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein]
potassium oxonate results in increased expression of SLC2A9 mRNA; potassium oxonate results in increased expression of SLC2A9 protein
[potassium oxonate co-treated with Hypoxanthine] results in increased expression of SLC2A9 protein; eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased expression of SLC2A9 protein]		 CTD PMID:21909718 PMID:22865646 PMID:22967667 PMID:38052408 NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981 		JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP
ISO		 [Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; potassium oxonate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
[Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]		 CTD PMID:20868668 PMID:33749747 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Umod uromodulin multiple interactions
increases expression
affects expression		 ISO 4-hydroxystilbene inhibits the reaction [potassium oxonate results in increased expression of UMOD protein]; Allopurinol inhibits the reaction [potassium oxonate affects the expression of UMOD protein]; Allopurinol inhibits the reaction [potassium oxonate results in increased expression of UMOD mRNA]; mulberroside A inhibits the reaction [potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein]; polydatin inhibits the reaction [potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein]; potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein; Probenecid inhibits the reaction [potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein]; pterostilbene inhibits the reaction [potassium oxonate results in increased expression of UMOD protein]; Quercetin inhibits the reaction [potassium oxonate affects the expression of UMOD protein]; Quercetin inhibits the reaction [potassium oxonate results in increased expression of UMOD mRNA]; Stilbenes analog inhibits the reaction [potassium oxonate results in increased expression of UMOD protein] CTD PMID:21909718 PMID:22865646 NCBI chr 1:173,816,341...173,829,681
Ensembl chr 1:173,816,339...173,830,302 		JBrowse link
G Xdh xanthine dehydrogenase multiple interactions ISO [Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein; Allopurinol inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein]; baicalein inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein]; baicalin inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein] CTD PMID:34044073 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19911
    chemical entity 19909
      atom 19909
        nonmetal atom 19832
          carbon atom 19785
            organic molecular entity 19785
              Potassium 2,6-dihydroxytriazinecarboxylate 16
Path 2
Term Annotations click to browse term
  CHEBI ontology 19911
    subatomic particle 19909
      composite particle 19909
        hadron 19880
          baryon 19880
            nucleon 19909
              atomic nucleus 19880
                atom 19909
                  main group element atom 19849
                    p-block element atom 19849
                      carbon group element atom 19766
                        carbon atom 19785
                          organic molecular entity 19785
                            Potassium 2,6-dihydroxytriazinecarboxylate 16
paths to the root